Prevention of venous thromboembolism in the hospitalized medical patient

Amir K. Jaffer, Alpesh N. Amin, Daniel Brotman, Steven B. Deitelzweig, Sylvia C. Mckean, Alex C. Spyropoulos

Research output: Contribution to journalArticle

Abstract

Hospitalized acutely ill medical patients are at high risk for venous thromboembolism (VTE), and clinical trials clearly demonstrate that pharmacologic prophylaxis of VTE for up to 14 days significantly reduces the incidence of VTE in this population. Guidelines recommend use of low-molecular-weight heparin (LMWH) or unfractionated heparin (5,000 U three times daily) for VTE prophylaxis in hospitalized medical patients with risk factors for VTE; in patients with contraindications to anticoagulants, mechanical prophylaxis is recommended. All hospitalized medical patients should be assessed for their risk of VTE at admission and daily thereafter, and those with reduced mobility and one or more other VTE risk factors are candidates for aggressive VTE prophylaxis. Based on results from the recently reported EXCLAIM trial, extended postdischarge prophylaxis with LMWH for 28 days should be considered for hospitalized medical patients with reduced mobility who are older than age 75 or have a cancer diagnosis or a history of VTE.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalCleveland Clinic Journal of Medicine
Volume75
Issue numberSUPPL.3
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Venous Thromboembolism
Low Molecular Weight Heparin
Anticoagulants
Heparin
Clinical Trials
Guidelines
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jaffer, A. K., Amin, A. N., Brotman, D., Deitelzweig, S. B., Mckean, S. C., & Spyropoulos, A. C. (2008). Prevention of venous thromboembolism in the hospitalized medical patient. Cleveland Clinic Journal of Medicine, 75(SUPPL.3), 7-16. https://doi.org/10.3949/ccjm.75.1.7

Prevention of venous thromboembolism in the hospitalized medical patient. / Jaffer, Amir K.; Amin, Alpesh N.; Brotman, Daniel; Deitelzweig, Steven B.; Mckean, Sylvia C.; Spyropoulos, Alex C.

In: Cleveland Clinic Journal of Medicine, Vol. 75, No. SUPPL.3, 2008, p. 7-16.

Research output: Contribution to journalArticle

Jaffer, AK, Amin, AN, Brotman, D, Deitelzweig, SB, Mckean, SC & Spyropoulos, AC 2008, 'Prevention of venous thromboembolism in the hospitalized medical patient', Cleveland Clinic Journal of Medicine, vol. 75, no. SUPPL.3, pp. 7-16. https://doi.org/10.3949/ccjm.75.1.7
Jaffer, Amir K. ; Amin, Alpesh N. ; Brotman, Daniel ; Deitelzweig, Steven B. ; Mckean, Sylvia C. ; Spyropoulos, Alex C. / Prevention of venous thromboembolism in the hospitalized medical patient. In: Cleveland Clinic Journal of Medicine. 2008 ; Vol. 75, No. SUPPL.3. pp. 7-16.
@article{5a5792d4d2744b73ae4e2fb92c5c588a,
title = "Prevention of venous thromboembolism in the hospitalized medical patient",
abstract = "Hospitalized acutely ill medical patients are at high risk for venous thromboembolism (VTE), and clinical trials clearly demonstrate that pharmacologic prophylaxis of VTE for up to 14 days significantly reduces the incidence of VTE in this population. Guidelines recommend use of low-molecular-weight heparin (LMWH) or unfractionated heparin (5,000 U three times daily) for VTE prophylaxis in hospitalized medical patients with risk factors for VTE; in patients with contraindications to anticoagulants, mechanical prophylaxis is recommended. All hospitalized medical patients should be assessed for their risk of VTE at admission and daily thereafter, and those with reduced mobility and one or more other VTE risk factors are candidates for aggressive VTE prophylaxis. Based on results from the recently reported EXCLAIM trial, extended postdischarge prophylaxis with LMWH for 28 days should be considered for hospitalized medical patients with reduced mobility who are older than age 75 or have a cancer diagnosis or a history of VTE.",
author = "Jaffer, {Amir K.} and Amin, {Alpesh N.} and Daniel Brotman and Deitelzweig, {Steven B.} and Mckean, {Sylvia C.} and Spyropoulos, {Alex C.}",
year = "2008",
doi = "10.3949/ccjm.75.1.7",
language = "English (US)",
volume = "75",
pages = "7--16",
journal = "Cleveland Clinic Journal of Medicine",
issn = "0891-1150",
publisher = "Cleveland Clinic Educational Foundation",
number = "SUPPL.3",

}

TY - JOUR

T1 - Prevention of venous thromboembolism in the hospitalized medical patient

AU - Jaffer, Amir K.

AU - Amin, Alpesh N.

AU - Brotman, Daniel

AU - Deitelzweig, Steven B.

AU - Mckean, Sylvia C.

AU - Spyropoulos, Alex C.

PY - 2008

Y1 - 2008

N2 - Hospitalized acutely ill medical patients are at high risk for venous thromboembolism (VTE), and clinical trials clearly demonstrate that pharmacologic prophylaxis of VTE for up to 14 days significantly reduces the incidence of VTE in this population. Guidelines recommend use of low-molecular-weight heparin (LMWH) or unfractionated heparin (5,000 U three times daily) for VTE prophylaxis in hospitalized medical patients with risk factors for VTE; in patients with contraindications to anticoagulants, mechanical prophylaxis is recommended. All hospitalized medical patients should be assessed for their risk of VTE at admission and daily thereafter, and those with reduced mobility and one or more other VTE risk factors are candidates for aggressive VTE prophylaxis. Based on results from the recently reported EXCLAIM trial, extended postdischarge prophylaxis with LMWH for 28 days should be considered for hospitalized medical patients with reduced mobility who are older than age 75 or have a cancer diagnosis or a history of VTE.

AB - Hospitalized acutely ill medical patients are at high risk for venous thromboembolism (VTE), and clinical trials clearly demonstrate that pharmacologic prophylaxis of VTE for up to 14 days significantly reduces the incidence of VTE in this population. Guidelines recommend use of low-molecular-weight heparin (LMWH) or unfractionated heparin (5,000 U three times daily) for VTE prophylaxis in hospitalized medical patients with risk factors for VTE; in patients with contraindications to anticoagulants, mechanical prophylaxis is recommended. All hospitalized medical patients should be assessed for their risk of VTE at admission and daily thereafter, and those with reduced mobility and one or more other VTE risk factors are candidates for aggressive VTE prophylaxis. Based on results from the recently reported EXCLAIM trial, extended postdischarge prophylaxis with LMWH for 28 days should be considered for hospitalized medical patients with reduced mobility who are older than age 75 or have a cancer diagnosis or a history of VTE.

UR - http://www.scopus.com/inward/record.url?scp=46349108458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46349108458&partnerID=8YFLogxK

U2 - 10.3949/ccjm.75.1.7

DO - 10.3949/ccjm.75.1.7

M3 - Article

C2 - 18494223

AN - SCOPUS:46349108458

VL - 75

SP - 7

EP - 16

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

SN - 0891-1150

IS - SUPPL.3

ER -